Objective: The purpose of this study was to determine whether the topical application of recombinant human platelet-derived growth factor gel influences healing after abdominal wound separation.
Study Design: A double-blinded randomized placebo-controlled trial was conducted in patients with surgical wound separation.
Results: Ten patients were randomized to treatment, and 11 patients were randomized to placebo. There was no difference between groups with regard to age, initial wound volume, type of surgical procedure, incision, or body mass index. Patients in the placebo group received 47 +/- 24 days of therapy. Patients in the treatment group received 29 +/- 14 days of therapy (P =.057). The wounds of the placebo group closed 54 +/- 26 days after operation. Wounds in the treatment group closed in 35 +/- 15 days (P =.05). Wound closure rates were significantly different, as determined by Kaplan-Meier analysis.
Conclusion: Our preliminary study suggests that the topical application of 0.01% recombinant human platelet-derived growth factor gel accelerates healing of separated surgical wounds. Additional studies will be required to determine comparative efficacy and effectiveness relative to the current clinical practice of wound granulation and secondary closure.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1067/mob.2002.121867 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A High-Throughput Immune-Oncology Screen Identifies Immunostimulatory Properties of Cytotoxic Chemotherapy Agents in TNBC.
Cancers (Basel)
December 2024
Department of Pharmacology, Vanderbilt University School of Medicine, Nashville, TN 37232, USA.
Triple-negative breast cancers (TNBCs) typically have a greater immune cell infiltrate and are more likely to respond to immune checkpoint inhibition (ICI) than ER+ or HER2+ breast cancers. However, there is a crucial need to optimize combining chemotherapy strategies with ICI to enhance overall survival in TNBC. Therefore, we developed a high-throughput co-culture screening assay to identify compounds that enhance CD8+ T-cell-mediated tumor cell cytotoxicity.
View Article and Find Full Text PDFDiscovery and Characterization of VU0542270, the First Selective Inhibitor of Vascular Kir6.1/SUR2B K Channels.
Mol Pharmacol
February 2024
Departments of Anesthesiology (K.L., S.J.M., J.S.D.), Pharmacology (K.L., C.H., J.D.B., U.R., O.B., C.W.L., J.S.D.), Pediatrics (E.L.S.), and Biochemistry (J.A.B.), Vanderbilt University Medical Center, Nashville, Tennessee and Vanderbilt Institute of Chemical Biology, Vanderbilt University, Nashville, Tennessee (J.A.B., E.L.D., J.S.D.)
Vascular smooth muscle K channels critically regulate blood flow and blood pressure by modulating vascular tone and therefore represent attractive drug targets for treating several cardiovascular disorders. However, the lack of potent inhibitors that can selectively inhibit Kir6.1/SUR2B (vascular K) over Kir6.
View Article and Find Full Text PDFModulation of Uptake and Reactivity of Nitrogen Dioxide in Metal-Organic Framework Materials.
Angew Chem Int Ed Engl
July 2023
Department of Chemistry, University of Manchester, Manchester, M13 9PL, UK.
We report the modulation of reactivity of nitrogen dioxide (NO ) in a charged metal-organic framework (MOF) material, MFM-305-CH in which unbound N-centres are methylated and the cationic charge counter-balanced by Cl ions in the pores. Uptake of NO into MFM-305-CH leads to reaction between NO and Cl to give nitrosyl chloride (NOCl) and NO anions. A high dynamic uptake of 6.
View Article and Find Full Text PDFSynthesis and SAR of a novel Kir6.2/SUR1 channel opener scaffold identified by HTS.
Bioorg Med Chem Lett
May 2023
Warren Center for Neuroscience Drug Discovery, Vanderbilt University, Nashville, TN 37232, USA; Department of Pharmacology, Vanderbilt University School of Medicine, Nashville, TN 37232, USA. Electronic address:
Kir6.2/SUR1 is an ATP-regulated potassium channel that acts as an intracellular metabolic sensor, controlling insulin and appetite-stimulatory neuropeptides secretion. In this Letter, we present the SAR around a novel Kir6.
View Article and Find Full Text PDFIdentification of Potent, Selective, and Peripherally Restricted Serotonin Receptor 2B Antagonists from a High-Throughput Screen.
Assay Drug Dev Technol
April 2023
Department of Biomedical Engineering, Vanderbilt University, Nashville, Tennessee, USA.
Antagonists of the serotonin receptor 2B (5-HT) have shown great promise as therapeutics for the treatment of pulmonary arterial hypertension, valvular heart disease, and related cardiopathies. Herein, we describe a high-throughput screen campaign that led to the identification of highly potent and selective 5-HT antagonists. Furthermore, selected compounds were profiled for their predicted ability to cross the blood-brain barrier.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!